Literature DB >> 10600134

Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling.

N M Tepe1, J N Lorenz, A Yatani, R Dash, E G Kranias, G W Dorn, S B Liggett.   

Abstract

The limiting element in beta-adrenergic receptor (betaAR)-G(s)-adenylyl cyclase (AC) signal transduction in the cardiomyocyte is not known, but it has been proposed that the level of adenylyl cyclase expression constrains betaAR signaling. To alter the above equilibrium, type V AC was overexpressed in a myocyte-specific manner in the hearts of transgenic mice using the alpha-myosin heavy chain promoter. Expression of type V AC was approximately 75% over endogenous levels as quantitated by [(3)H]forskolin binding. Functional activity of the transgene product was evident in cardiac membrane AC studies, where basal (45 +/- 11 vs 19 +/- 5 pmol min(-)(1) mg(-)(1)) and forskolin+Mn(2+) (695 +/- 104 vs 386 +/- 34 pmol min(-)(1) mg(-)(1)) stimulated activities were increased compared to activities in nontransgenic (NTG) littermates. However, while isoproterenol stimulated activities were higher (74 +/- 12 vs 46 +/- 9.8 pmol min(-)(1) mg(-)(1)), the fold stimulation over basal was not increased in ACV overexpressors compared to NTG (line 14.3 = 2.29 +/- 0.44-fold, line 15.1 = 1.70 +/- 0.1-fold, NTG = 2.62 +/- 0.18-fold). Similarly, in whole cell patch-clamp studies, betaAR-mediated opening of L-type Ca(2+) channels was not found to be enhanced in transgenic ACV myocytes (225 +/- 15 vs 216 +/- 10% of basal currents). Basal and isoproterenol stimulated PKA activities were elevated in the ACV mice compared to NTG, but again the extent of stimulation over basal was not enhanced. Phosphorylated phospholamban was approximately 2-fold greater in myocytes from ACV hearts compared to NTG, indicating that distal elements of the contractile cascade are activated by AC overexpression. ACV mice displayed increased heart rates and fractional shortening as assessed by echocardiography. However, in vivo hemodynamic studies revealed that heart rate and contractility responses to agonist infusion were not enhanced in ACV mice compared to NTG. We conclude that at native stoichiometries, the levels of adenylyl cyclase influence basal activities and cardiac function, but do not constrain betaAR signaling in the cardiomyocyte.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600134     DOI: 10.1021/bi991619k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

Review 1.  Beta-adrenergic receptors in the failing heart: the good, the bad, and the unknown.

Authors:  S B Liggett
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.

Authors:  Gerald W Dorn; Stephen B Liggett
Journal:  Mol Pharmacol       Date:  2009-06-02       Impact factor: 4.436

Review 3.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

4.  Type 5 adenylyl cyclase plays a major role in stabilizing heart rate in response to microgravity induced by parabolic flight.

Authors:  Satoshi Okumura; Takashi Tsunematsu; Yunzhe Bai; Qibin Jiao; Shinji Ono; Sayaka Suzuki; Reiko Kurotani; Motohiko Sato; Susumu Minamisawa; Satoshi Umemura; Yoshihiro Ishikawa
Journal:  J Appl Physiol (1985)       Date:  2008-05-01

Review 5.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

6.  Bitransgenesis with beta(2)-adrenergic receptors or adenylyl cyclase fails to improve beta(1)-adrenergic receptor cardiomyopathy.

Authors:  Natalia Petrashevskaya; Brigitte R Gaume; Kathryn A Mihlbachler; Gerald W Dorn; Stephen B Liggett
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

7.  Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor.

Authors:  Jason M Conley; Cameron S Brand; Amy S Bogard; Evan P S Pratt; Ruqiang Xu; Gregory H Hockerman; Rennolds S Ostrom; Carmen W Dessauer; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2013-09-05       Impact factor: 4.030

Review 8.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

9.  Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs.

Authors:  Steven M Swift; Brigitte R Gaume; Kersten M Small; Bruce J Aronow; Stephen B Liggett
Journal:  Physiol Genomics       Date:  2008-07-29       Impact factor: 3.107

10.  Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction.

Authors:  Stéphanie M Pontier; Yann Percherancier; Ségolène Galandrin; Andreas Breit; Céline Galés; Michel Bouvier
Journal:  J Biol Chem       Date:  2008-06-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.